Skip to main content

Table 1 Patient and imaging characteristics of the 102 patients including 51 breast cancer cases and 51 matched controls with biopsy-proven benign lesions

From: Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer

Patient/imaging characteristics Cancer cases (n = 51) Controls (n = 51)
Diagnostic BI-RADS findings in single-side breast on mammography and/or ultrasound
 Breast with lesion (cancer/benign) BI-RADS 4 11 (22 %) 47 (92 %)
BI-RADS 5 40 (78 %) 4 (8 %)
 Contralateral (studied) breast BI-RADS 1 27 (53 %) 21 (41 %)
BI-RADS 2 19 (37 %) 25 (49 %)
BI-RADS 3 1 (2 %) 1 (2 %)
BI-RADS 4 4 (8 %) 4 (8 %)
BI-RADS 5 0 (0 %) 0 (0 %)
Age, years, mean ± SD (range) 47.6 ± 7.4 (34–60) 47.1 ± 7.3 (31–60)
Menopausal status
 Premenopausal 28 (55 %) 30 (59 %)
 Postmenopausal 23 (45 %) 21 (41 %)
Known pathogenic BRCA1/2 mutation 2 (4 %) 0 (0 %)
History of prior breast cancer 0 (0 %) 0 (0 %)
Family history of breast cancer 26 (51 %) 31 (61 %)
Family history of ovarian cancer 3 (6 %) 0 (0 %)
Prior biopsy (>1 year prior to the studied biopsy)
 Atypia 1 (2 %) 0 (0 %)
 Benign abnormality 9 (18 %) 6 (12 %)
Exogenous hormone use
 Hormone replacement therapy 7 (14 %) 5 (10 %)
 Birth control pills 33 (65 %) 34 (67 %)
 Tamoxifen 1 (2 %) 0 (0 %)
 None 5 (10 %) 12 (24 %)
 Oophorectomy 0 (0 %) 0 (0 %)
Mammographic density (visual BI-RADS density description)
 Fatty 2 (4 %) 1 (2 %)
 Scattered fibroglandular density 14 (27 %) 13 (25 %)
 Heterogeneously dense 32 (63 %) 33 (65 %)
 Extremely dense 3 (6 %) 4 (8 %)
Background parenchymal enhancement, BPE%, mean ± SD (range) 44.6 ± 8.9 (20.9–62.0) 39.8 ± 11.4 (17.9–61.6)
Kinetics imaging measures, mean ± SD (range)
Wash-in slope variance × 100 (unit) 2.90 ± 2.72 (0.48–15.42) 1.75 ± 1.26 (0.43–6.87)
Signal enhancement ratio volume, cm3 118.9 ± 85.6 (26.1–429.8) 80.4 ± 42.9 (21.1–194.5)
  1. Data are numbers of subjects, with percentages in parentheses, unless stated otherwise. BI-RADS Breast Imaging-Reporting and Data System